OR WAIT null SECS
German-based company, Insilico Biotechnology, has announced that it has opened its first subsidiary in the United States, specifically in Boston, MA, which is a biopharmaceutical hub in the country.
German-based company, Insilico Biotechnology, has announced in a Feb. 27, 2020 press release, that it has opened its first subsidiary in the United States, specifically in Boston, MA, which is a biopharmaceutical hub in the country.
The US subsidiary, Insilico Biotechnology Corp., is expected to provide the company with access to growth opportunities, as a result of the size of the market, and will allow the company to strengthen its relationship with its customers based in the US. In addition to developing the US business, the company will provide consulting and services for existing customers.
“Following the opening of the representative office in Singapore, the foundation of the Boston subsidiary is a strategic step to achieve our vision of serving the global biopharmaceutical market as the leading provider of predictive solutions for smart biofactories,” said Klaus Mauch, CEO of Insilico, in the press release.
Brett Lepore, the newly appointed president of Insilico Biotechnology Corp., added, “I am extremely happy about being able to directly contribute to our customers’ successful digital transformation with Insilico as their partner. I am absolutely positive that this is the right time and that Boston is exactly the right place.”
Source: Insilico Biotechnology